Prader-Willi Syndrome: Emerging Therapies
Prader-Willi syndrome is a rare genetic condition characterized by physical and behavioral problems, including an uncontrollable appetite.
A notable feature of the condition is hyperphagia, or feeling hungry all the time.
This year, the U.S. Food and Drug Administration (FDA) approved VYKAT XR, developed by Soleno Therapeutics, to address hyperphagia.
VYKAT XR, made of diazoxide choline, heightens satiety in people, making it the first and only approved drug to treat hyperphagia.
Several other treatments are being trialed, each working differently to address various symptoms of the syndrome.
Author's summary: Prader-Willi syndrome therapies are advancing towards FDA approval.